GlassScriptPhysician profile
Elissa S Stecker
NPI 1295056000
$880.86
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $482 · 2020: $191 · 2021: $22.85 · 2022: $52.53 · 2024: $133.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $133.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $132.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $132.91 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $112.01 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $107.52 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $81.22 | 2019-2020 | |
| Novo Nordisk INC | $77.32 | 2019-2022 | |
| Amarin Pharma, INC. | $67.89 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $62.35 | 2019-2021 | |
| Pfizer INC. | $61.29 | 2019-2022 | |
| Lilly USA, LLC | $58.08 | 2019-2020 | |
| Amgen INC. | $52.99 | 2019 | |
| Glaxosmithkline, LLC. | $33.61 | 2020 | |
| Novartis Pharmaceuticals Corporation | $16.88 | 2019 | |
| Allergan, INC. | $16.79 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elissa Stecker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.